Immunoglobulin superfamily

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Neoplasm, SD, Marketing, ASH, DCR, B-cell lymphoma, American Society of Clinical Oncology, Research, Junshi, COVID-19, Lilly, NMPA, Clinical trial, Oncology, FDA, Lymphoma, Safety, Bamlanivimab, Cancer, PD-1, Social responsibility, Immunoglobulin superfamily, Dor, DLT, Society, CD28, Hodgkin lymphoma, HL, ASCO, TNF, ORR, Bamlanivimab/etesevimab, Ira Pastan, NHL, SSE, Development, Patient, Time-invariant system, HVEM, Poster, Microbiology, BTLA, EUA, HKEX, Lymphocyte, Infection, Autoimmunity, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Vaccine, Medical imaging, Science, Chinese, Hematology

SHANGHAI, China, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas in a poster at the 64th American Society of Hematology (ASH) Annual Meeting. Tifcemalimab is the world’s first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.

Key Points: 
  • The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation.
  • “However, if PD-1 inhibitors fail, there is no standard treatment to resort to, thus new treatment methods are urgently needed in clinical practice.
  • This is the very first time an anti-BTLA antibody was evaluated for safety and efficacy in the treatment of lymphomas.
  • Now, updated results from the clinical trial for lymphomas have been presented at the ASH annual meeting.

Global LAG 3 Inhibitor Market Opportunity & Clinical Trials Insight Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022
Health, Clinical Trials, NK, Infection, Immunoglobulin superfamily, Patient, TIL, Therapy, Cell, PD-1, Diabetes, Non-Hodgkin lymphoma, Lung, Nivolumab, Cancer, IMP321, Stomach, Ono Pharmaceutical, Multiple myeloma, Immunotherapy, Adoption, US, Degenerative disease, Cell cycle, HIV, Hope, Neoplasm, Company, TILS, PD-L1, Melanoma, Bristol Myers Squibb, Leukemia, Monoclonal antibody, Merck, Histocompatibility, US FDA, Apoptosis, Novartis, Breast cancer, Macrogen, Immutep, Lymphoma, Multiple sclerosis, B cell, Antibody, Relatlimab, Autoimmunity, LAG3, Pharmaceutical industry, Vaccine

The "Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • The key players in the market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, among others.
  • Cancer immunotherapy is a novel approach which can reverse tumor immune escape by suppressing immune checkpoint pathways.
  • Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
    LAG 3 Inhibitors Trials By Phase, Company, Country, Indication

NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Clusters of differentiation, Immunoglobulin superfamily, Medical specialties, Clinical medicine, LILRB1, LILRB2, Antibody, Biomarker, Cancer immunotherapy, Immunoglobulin therapy

NGM707 is a novel dual antagonist antibody that inhibits the Immunoglobulin-like Transcript 2 (ILT2) and Immunoglobulin-like Transcript 4 (ILT4) receptors.

Key Points: 
  • NGM707 is a novel dual antagonist antibody that inhibits the Immunoglobulin-like Transcript 2 (ILT2) and Immunoglobulin-like Transcript 4 (ILT4) receptors.
  • As a result, we believe NGM707 offers a potentially compelling treatment profile and could represent an important therapeutic advancement for patients with cancer.
  • NGM707 was designed with the goal of improving patient immune responses to tumors by inhibiting both the ILT2 and ILT4 receptors.
  • Both the Phase 1 and Phase 2 portions of the study will provide the opportunity to evaluate correlations between biomarker changes and clinical outcomes.

NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors

Retrieved on: 
Wednesday, December 9, 2020
Immunoglobulin superfamily, Clusters of differentiation, Branches of biology, LAIR1, Cell biology, LILRB1, LILRB2, Stromal cell, LAIR2, Collagen receptor

LAIR1 is a collagen-binding inhibitory receptor expressed on immune cells1-2 that is implicated in immune suppression.

Key Points: 
  • LAIR1 is a collagen-binding inhibitory receptor expressed on immune cells1-2 that is implicated in immune suppression.
  • LAIR1 and collagens are upregulated in multiple cancer types3-7 where collagens are produced by activated stromal cells.
  • Designed to inhibit LAIR1 interactions with stromal-derived collagens, NGM438 has the potential to block this stromal checkpoint and restore anti-tumor immune responses.
  • NGM707 is a novel dual antagonist antibody that inhibits Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4).

Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism

Retrieved on: 
Monday, November 16, 2020
Clusters of differentiation, Immunoglobulin superfamily, LILRB2, Programmed cell death protein 1

JTX-8064 is an anti-Leukocyte Immunoglobulin Like Receptor B2 (LILRB2/ILT4) antibody and is the first tumor-associated macrophage candidate from Jounces Translational Science Platform.

Key Points: 
  • JTX-8064 is an anti-Leukocyte Immunoglobulin Like Receptor B2 (LILRB2/ILT4) antibody and is the first tumor-associated macrophage candidate from Jounces Translational Science Platform.
  • Through the Study May Proceed Letter, the FDA has cleared the original Investigational New Drug (IND) application for JTX-8064.
  • A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with a PD-1 inhibitor is planned to begin enrollment by year-end 2020.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2

Retrieved on: 
Tuesday, November 10, 2020
Cancer treatments, Clinical medicine, Medicine, Immune system, Cancer immunotherapy, Clusters of differentiation, Orphan drugs, Agenus, Immunoglobulin superfamily, Pembrolizumab, Immune checkpoint, LILRB2

We are excited about the progress of MK-4830 and look forward to delivering our own wholly-owned novel myeloid tuning agent to the clinic next year.

Key Points: 
  • We are excited about the progress of MK-4830 and look forward to delivering our own wholly-owned novel myeloid tuning agent to the clinic next year.
  • Under its Royalty Purchase Agreement with XOMA LLC, Agenus retains 90% of all milestones from Merck and 67% of future royalties.
  • MK-4830 is a novel antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4).
  • Merck is conducting a Phase 1 study of MK-4830 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (NCT03564691).

Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020

Retrieved on: 
Wednesday, April 29, 2020
Life sciences, Companies, Industries, Bristol-Myers Squibb, Celgene, Summit, New Jersey, Immunoglobulin superfamily, LILRB2, Conference call, Dial

Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m.
  • To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 4044098.
  • The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com .
  • In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene Corporation, a wholly-owned subsidiary of Bristol-Myers Squibb Company.

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020

Retrieved on: 
Friday, February 21, 2020
Life sciences, Companies, Industries, Bristol-Myers Squibb, Celgene, Summit, New Jersey, Immunoglobulin superfamily, LILRB2, Conference call, Dial

Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m.
  • To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 7889239.
  • The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com .
  • In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene Corporation, a wholly-owned subsidiary of Bristol-Myers Squibb Company.

MiLaboratories' MiXCR Immune Repertoire Analyzer version 2.1.11 is now available at Illumina BaseSpace™

Retrieved on: 
Monday, November 4, 2019
Medical specialties, Branches of biology, Immunology, Medicine, Immune repertoire, V(D)J recombination, Antibody, Illumina, Inc., T-cell receptor, Immunoglobulin superfamily

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- MiLaboratories LLC, a technology leader in T-cell receptor (TCR) and immunoglobulin (IG) repertoire profiling, reports that an upgraded version of its flagship software product, MiXCR, is now officially available as an Illumina BaseSpace application ( https://www.illumina.com/products/by-type/informatics-products/basespace... ).

Key Points: 
  • SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- MiLaboratories LLC, a technology leader in T-cell receptor (TCR) and immunoglobulin (IG) repertoire profiling, reports that an upgraded version of its flagship software product, MiXCR, is now officially available as an Illumina BaseSpace application ( https://www.illumina.com/products/by-type/informatics-products/basespace... ).
  • MiXCR is a "gold standard" analytical package in the area of T-cell receptors (TCR) and immunoglobulin (IG) repertoire profiling.
  • "This release of MiXCR Immune Repertoire Analyzer brings mature versions of our algorithms for repertoire extraction from any type of sequencing data.
  • "We are excited to work with MiLaboratory to offer theirMiXCRpipeline onBaseSpace Sequence Hub," said Kevin Meldrum, VP Product Development at Illumina.

Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019

Retrieved on: 
Thursday, October 31, 2019
Natural sciences, Physics, Physical sciences, Immunoglobulin superfamily, Bristol-Myers Squibb, Celgene, Summit, New Jersey, LILRB2, Conference call, Jounce, Lluís Companys

Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m.
  • To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 3379867.
  • The live webcast can be accessed under Events & Presentations in the Investors and Media section of the companys website at www.jouncetx.com .
  • In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene.